ERBB2 and breast carcinoma: HR-positive HER2-negative breast cancer accounts for approximately 60% of all primary breast cancer cases, and approximately 20% of early estrogen receptor (ER)-positive patients may experience local or distal recurrence after treatment (1, 2).